SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim data from its RAD 101 Phase 2b imaging trial, sparking significant community discussion around the potential for a short squeeze and high price targets. The stock's impressive pre-market surge and subsequent volatility have traders weighing the potential for further gains against the risk of a pullback. A forthcoming webinar is adding to the anticipation, with many speculating on its impact on the stock's direction.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to speculation of a potential short squeeze, with community members actively discussing strategies to push the stock higher and liquidate shorts. The stock's high volatility and recent price action are fueling the conversation, as traders compare it to other low-float stocks that have experienced significant surges. Some are noting the company's small market cap and low float, which could contribute to rapid price movements.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, driven by sector-wide concerns about an AI bubble and delayed data center projects, despite a major Microsoft deal. Community sentiment is divided, with some calling the stock a "scam" and expecting further declines, while others view the dip as a buying opportunity, citing strong fundamentals and long-term growth potential. Discussions also revolve around potential market manipulation and the stock's correlation with Bitcoin's price movements.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chun Sing Chan on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending as traders discuss its low float and potential for a short squeeze, drawing comparisons to other HK stocks that have seen explosive runs. Community members are highlighting the company's recent acquisitions and revenue, anticipating news that could catalyze a significant price movement. Some traders caution against FOMO due to the stock's volatility and low volume.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's stock is trending amid discussions around its AI strategy and potential partnerships, particularly after some analysts suggested it's lagging behind competitors. The community is debating whether Apple's lower AI spending is a strength or weakness, with some viewing it as a safe haven play. Additionally, there's speculation about Apple's next moves in response to increasing competition and evolving market dynamics.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending as community members discuss the potential impact of autonomous driving tests and analyst upgrades. Bullish sentiment is fueled by the possibility of Tesla achieving new highs, while bears express concerns about valuation. Options activity and overall market conditions are also contributing to the conversation around the stock.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

OMER is trending as investors anticipate a potential FDA approval for Narsoplimab by late December, with the community actively discussing the likelihood of approval and potential buyout scenarios. Recent price action and large put buys have sparked speculation about a possible news leak or market manipulation. Bullish investors express confidence in the drug's efficacy and Novo Nordisk's backing, viewing any price dips as buying opportunities.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest news of a potential $19.5 billion write-down related to its EV strategy, with community discussions focusing on the implications of scaling back EV investments and shifting towards hybrids. Some view this pullback as a pragmatic move aligning with current market demand and improving profitability, while others question the company's leadership and long-term EV commitment. Broader conversations include the impact on Tesla and potential industry-wide EV write-downs.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is trending as investors discuss its recent QQQ removal and significant YTD decline, leading to debates about tax-loss harvesting and potential bottom fishing. Community members are weighing the impact of these factors against the company's fundamentals and future prospects in the ad tech space. Discussions also involve the company's leadership and strategic direction amidst competitive pressures.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as the community rallies around its meme-driven culture and consistent presence, emphasizing fun and organic growth on the Solana blockchain. Community members highlight the coin's unique ability to maintain bullish vibes regardless of market conditions, promoting it as a 'virus' that is both inevitable and enjoyable to embrace. Discussions also revolve around the coin's potential for long-term growth, particularly looking ahead to 2026, and its growing presence in the meme space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company expects gross proceeds of about $60 million from the offering, which it intends to use for general corporate purposes.</li><li>Pasithea expects the offering to close on or about December 1.</li></ul>Pasithea Therapeutics Corp. (KTTA) on Friday announced the pricing of a public offering of 80 million shares of the company’s common stock at $0.75 per share.KTTA shares traded 43% higher on Friday morning at the time of writing.<h2 class="st-heading-2">Offering Proceeds And Purpose</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/28/3196323/0/en/Pasithea-Therapeutics-Announces-Pricing-of-60-Million-Public-Offering-of-Common-Stock.html">expects</a> gross proceeds of about $60 million from the offering, which it intends to use for general corporate purposes such as ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, and investing in or acquiring companies that are synergistic with or complementary to the company’s technologies, among others.The offer price represents a 29% discount to the stock’s Wednesday closing price.The company said that it expects the offering, led by investors including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management, to close on or about December 1. The offering will extend its cash runway through at least the first half of 2028, it added. &nbsp;Earlier this month, the company was awarded a Hoffman ALS Clinical Trial Award grant worth about $1 million to study its lead drug candidate, PAS-004, in Amyotrophic lateral sclerosis (ALS) patients. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, where patients eventually lose the ability to breathe.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KTTA">KTTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user opined that the stock will erode its gains to hit $0.75 level.<stembedurl>https://stocktwits.com/GABBYGIRL/message/637652497</stembedurl>KTTA stock is down by 52% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/china-byd-recalls-nearly-89000-evs/cL5aGIxRELP">China’s BYD Recalls Nearly 89,000 EVs – Regulator Cites Battery Output Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Why Did KTTA Stock Soar A Whopping 43% Today?

The company announced the pricing of a public offering of 80 million shares of its common stock and said that the offering will extend its cash runway through at least the first half of 2028.

Equity

The company announced the pricing of a public offering of 80 million shares of its common stock and said that the offering will extend its cash runway through at least the first half of 2028.


<ul class="summary-bullets"><li>The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October.</li><li>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company said.</li><li>The company said it will carefully evaluate and consider Lynx1 Master Fund’s indication of interest in connection with its review of strategic alternatives.</li></ul> Neuphoria Therapeutics Inc. (NEUP) initiated a review of strategic alternatives, including potential acquisitions, on Tuesday to advance its pipeline programs and maximize shareholder value.NEUP shares traded 4% higher in the pre-market session at the time of writing.<h2 class="st-heading-2">Strategic Alternatives Under Consideration</h2>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.neuphoriatx.com/news-releases/news-release-details/neuphoria-announces-initiation-strategic-review-maximize">said.</a>The company added that it does not have a defined timeline for exploring strategic alternatives. Further, it is not confirmed that the process will result in a transaction.The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October after a late-stage trial missed its primary and secondary endpoints. Neuphoria then also said it will assess new development paths for BNC210 as a treatment for post-traumatic stress disorder (PTSD).<h2 class="st-heading-2">Lynx1 Master Fund Expresses Interest</h2>Neuphoria on Tuesday also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. The company said it will carefully evaluate and consider this indication of interest in connection with its review of strategic alternatives.Lynx1 Master Fund LP also expressed intent to nominate certain individuals to stand for election to Neuphoria’s Board of Directors at the company’s 2025 Annual Meeting of Stockholders, the company said. Neuphoria’s Board of Directors will now review the proposed director nominees. The annual meeting is scheduled for December 12.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NEUP">NEUP stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:623/62;" src="data:image/png;base64,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" width="623" height="62" alt="NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits"><figcaption>NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits</figcaption></figure>NEUP stock is up by 43% this year and by 11% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/poet-technologies-and-quantum-computing-team-up-to-boost-ai-data-speeds/cLPdoHVREPl">POET Technologies And Quantum Computing Team Up To Boost AI Data Speeds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition

Neuphoria also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. 

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

5 ETFs That Beat the Market in the First Half of 2025

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

Shares of Mind Medicine Inc. climbed over 2% on Tuesday afternoon, on track to break a two-session losing streak, as Evercore ISI initiated coverage with an&nbsp;‘Outperform’&nbsp;rating and a bullish $23 price target, suggesting over 200% upside from current levels.Evercore analysts highlighted the company’s innovation in developing a novel oral formulation of LSD, with its lead asset MM120 targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD).&nbsp;The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.Last month, Chardan initiated coverage with a&nbsp;‘Buy’ rating and a $20 price target, citing MM120’s potential to deliver over $1 billion in peak sales by 2026, assuming positive trial data and a strong commercial launch.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_and_message_volume_Jan_28_9a6374b37a.png" alt="MNMD sentiment and message volume Jan 28.png" width="1318" height="324"><figcaption>MNMD sentiment and message volume Jan 28 as of 12:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for Mind Medicine turned ‘bullish’ from ‘neutral,’ with increased message volume reflecting optimism.&nbsp;<stembedurl>https://stocktwits.com/EMT6/message/601825856</stembedurl><stembedurl>https://stocktwits.com/MichaelNaussCMT/message/601770767</stembedurl>Analysts expect sentiment to improve further in 2025, as the company nears key catalysts, including pivotal trial updates.Mind Medicine recently launched a Phase 3 trial of MM120 in GAD and expanded its intellectual property protection through 2041 by obtaining a patent for an orally disintegrating tablet (ODT) formulation.&nbsp;The Nasdaq Biotechnology Index (NBI) added the stock in December, which analysts noted could bolster institutional interest.The company ended the third quarter of 2024 with $295.28 million in cash and $24.31 million in debt.&nbsp;<a href="https://stocktwits.com/symbol/MNMD">Mind Medicine</a> recently said it raised $250 million last year through two equity financings.The small-cap biotech’s stock has returned about 90% over the past 12 months, though its short interest stands at 13.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company’s lead asset MM120 targets generalized anxiety disorder (GAD) and major depressive disorder (MDD). | Image source: Getty Images

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms. 

Shares of Cybin, Inc. (<a class="mention" data-mention="$CYBN" data-symbol-id="CYBN" href="https://stocktwits.com/symbol/CYBN" target="_blank">$CYBN</a>) surged as much as 10% on Monday, reaching their highest level since May, following the announcement of “unprecedented” 12-month efficacy data from a Phase 2 study of the biopharma’s major depressive disorder (MDD) treatment.The company reported that two 16 mg doses of CYB003, a proprietary deuterated psilocin program, spaced three weeks apart, showed “consistent, robust, and sustained” treatment benefits through the 12-month follow-up.&nbsp;This data supports the potential of CYB003 as an adjunctive treatment for MDD patients who have not achieved remission with first-line antidepressants, Cybin said.The U.S. Food and Drug Administration (FDA) recently granted CYB003 Breakthrough Therapy Designation, accelerating its review process.Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.&nbsp;“We are quite possibly witnessing a watershed moment in mental health care treatment paradigms and practices,” he said.Drysdale emphasized that current treatments, such as esketamine and electroconvulsive therapy (ECT), require up to 36 outpatient visits per treatment cycle, creating a significant burden on both patients and healthcare facilities.&nbsp;In contrast, CYB003’s two-dose treatment regimen could offer a more patient-friendly, long-lasting alternative.On Stocktwits, retail sentiment for CYBN turned ‘extremely bullish,’ with users expressing optimism about the future of the company and its potential impact on mental health care.&nbsp;Some users pointed to potential regulatory support under a Trump administration, suggesting that prominent figures like Robert F. Kennedy Jr. as HHS Secretary could expedite FDA approval for CYB003.<stembedurl>https://stocktwits.com/PsychedStocks/message/592985335</stembedurl>Another hoped that the stock would double to $25 soon.&nbsp;<stembedurl>https://stocktwits.com/DJTHollaAtMe/message/593002464</stembedurl>Analyst firms remain optimistic, even as Canaccord maintained a ‘Buy’ rating while lowering its price target to $86 from $96 last week.&nbsp;Alliance Global Partners, meanwhile, raised its target to $25 from $6, reflecting the potential upside based on CYB003’s progress and ongoing Phase 3 trials.Still, Cybin’s stock has seen a 19% decline year-to-date.&nbsp;For updates and corrections, email newsroom@stocktwits.comRead next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lbrt-stock-rises-as-ceo-to-join-trump-cabinet/cJ4vdwSRQe">Liberty Energy Stock Pops Following CEO’s Nomination To Trump’s Cabinet: Retail Buzz Grows</a>

The U.S. Food and Drug Administration (FDA) recently granted Cybin's CYB003 Breakthrough Therapy Designation, accelerating its review process.

Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish

Cybin's CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.

Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.

Quantum BioPharma (QNTM), formerly FSD Pharma Inc. (HUGE), has seen a surge in retail investor interest over the past week while notching gains of over 7%.Earlier this month, FSD Pharma underwent a significant transformation. The company consolidated its shares to increase the price to $18 per share and meet Nasdaq listing requirements. It was also rebranded as Quantum BioPharma (QNTM).Quantum also conducted a private placement, offering new shares to existing Class A shareholders. This move aimed to restore voting rights to the Class A shares, aligning them closer to their pre-2018 public offering levels.Adding to the recent buzz is the company's investment in Celly Nutrition, specifically their "unbuzzd" product — a drink designed to accelerate metabolism and aid in faster recovery from alcohol consumption.It's set to launch as powder packs on Amazon later this month, with ready-to-drink versions planned for later in the year.To support the release of unbuzzd, FSD Pharma launched a round of financing via the sale of 6,833,332 shares of HUGE stock at $203,469. The company has the option to sell more shares to raise additional funds.Several retail investors on Stocktwits were talking about unbuzzd, with some users sharing screenshots of the product available for purchase on Amazon on Monday.<stembedurl>https://stocktwits.com/ImYourDaddyy/message/584111359</stembedurl>This coincided with a surge in trading volume of QNTM, exceeding double its daily average of about 24,000 shares.However, the Amazon product link for unbuzzd on its official site currently leads to a "not found" page.<stembedurl>https://stocktwits.com/singa_stock/message/584171177</stembedurl>Currently, retail sentiment on Stocktwits for QNTM has turned 'neutral' (45/100) from 'bearish' a week ago.&nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/QNTM"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QNTM_sentiment_and_message_volume_Aug_26_2ce78f9e9d.png" alt="QNTM sentiment and message volume Aug 26.png" width="1310" height="316"></a><figcaption>QNTM sentiment and message volume Aug 26</figcaption></figure>&nbsp;Read Next: <a href="https://stkt.co/4CnRWSRT">Xpeng Stock Jumps, Retail Turns ‘Bullish’ After CEO Boosts Stake</a>&nbsp;&nbsp;&nbsp;&nbsp;

Quantum BioPharma-backed Celly Nutrition's Unbuzzd

Quantum Biopharma Stock (QNTM) Sees Retail Following Skyrocket Over 2,500% In A Week

Quantum BioPharma (QNTM), formerly FSD Pharma Inc. (HUGE), has seen a surge in retail investor interest over the past week while notching gains of over 7%.

QNTM Sees Retail Following Skyrocket Over 2,500% In A Week

The heightened focus comes after a series of strategic moves by the company, including rebranding, share consolidation, and an upcoming product launch.  


Current Price	$19.20
Prev Close	$19.81
Open	$19.82
Dividend Yield	N/A
50-Day Moving Average	$19.14
Beta	N/A
Avg. Volume	13,415.47
PE Ratio	N/A

52-Week High	$21.61
52-Week Low	$9.58
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PSIL
AdvisorShares Psychedelics ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PSIL News

PSILAdvisorShares Psychedelics ETF